# Blood count, kidney and liver monitoring during lutetium-177 radioligand therapy

Source: https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/  
OnCo record `blood-count-and-kidney-monitoring-during-radioligand-therapy` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lutetium-177 treatments (Lutathera, Pluvicto) can lower blood counts and affect the kidneys and liver. Blood is tested before every dose, and a dose may be delayed, reduced or stopped if results fall too far. With Lutathera, an amino acid drip protects the kidneys. Tell your team right away about bleeding, bruising, fever or passing much less urine. Your own team's plan comes first.

## Summary

This page sets the US labels beside the EU product information for two radioligand medicines, with the nuclear medicine societies' procedure documents. It is for understanding care; the treating team's own protocol comes first. Lutetium-177 dotatate: the EU SmPC lists minimum tests before each infusion (haemoglobin, white cells with differential, platelets; serum creatinine and Cockcroft-Gault clearance; ALT, AST, albumin, INR, bilirubin), once in the 2 to 4 weeks before and shortly before, then every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter; the US label says to monitor the same things and gives no schedule. The dose table is the same in both: thrombocytopenia from grade 2, anaemia or neutropenia from grade 3, creatinine clearance below 40 mL/min or a 40% change from baseline, and bilirubin above 3 times the upper limit of normal or albumin below 30 g/L with INR above 1.5 each mean withholding, resuming at 3.7 GBq, returning to 7.4 GBq if tolerated, and stopping for good on recurrence or if the interval would pass 16 weeks. Lymphopenia alone needs no dose change. An infusion of L-lysine and L-arginine starts 30 minutes before the dose; only the EU text requires serum potassium to be tested before it. Lutetium-177 vipivotide tetraxetan: grade 2 myelosuppression withholds; grade 3 or higher withholds and reduces by 20% to 5.9 GBq, once, with no return to full dose. The clearance threshold for withholding is below 30 mL/min in the US label and below 50 mL/min in the EU SmPC. The EANM/SNMMI guideline words several of these rules differently.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: blood tests before Lutathera; blood tests before Pluvicto; low blood counts on Lutathera; low blood counts on Pluvicto; myelosuppression on radioligand therapy; lymphopenia on lutetium-177; kidney protection with amino acids during PRRT; lysine and arginine infusion; Lutathera dose reduction; Pluvicto dose reduction; renal toxicity of lutetium-177; hyperkalaemia with the amino acid infusion

## Connected records

- protocols: [Dry mouth from radioactive iodine, PSMA radioligand therapy and cancer drugs](https://onco.cc/protocols/dry-mouth-from-cancer-drugs-and-radionuclide-therapy/), [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/), [Radiation safety at home after lutetium-177 PSMA or dotatate therapy](https://onco.cc/protocols/lutetium-177-therapy-home-radiation-safety/), [Red cell and platelet transfusion thresholds in cancer care](https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/), [Release of patients after radionuclide therapy or a permanent implant: criteria, instructions and records](https://onco.cc/protocols/radionuclide-therapy-patient-release-criteria/), [Renal dose adjustment of anticancer drugs in reduced kidney function](https://onco.cc/protocols/renal-dose-adjustment-of-anticancer-drugs/), [Second cancers caused by cancer drugs: monitoring on PARP inhibitors, BRAF inhibitors, lenalidomide, tamoxifen, radioligands and CAR T cells](https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/), [Suspected febrile neutropenia (neutropenic sepsis): the first hour](https://onco.cc/protocols/febrile-neutropenia-first-hour/)
- technologies: [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/)
- drugs: [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- terms: [Anaemia](https://onco.cc/terms/anaemia/), [Neutropenia](https://onco.cc/terms/neutropenia/), [PRRT (peptide receptor radionuclide therapy)](https://onco.cc/terms/prrt-term/), [Thrombocytopenia](https://onco.cc/terms/thrombocytopenia/)

---
JSON: https://onco.cc/api/v1/entities/blood-count-and-kidney-monitoring-during-radioligand-therapy.json